Haemonetics Co. (NYSE:HAE) Short Interest Update

Haemonetics Co. (NYSE:HAE) saw a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 1,429,100 shares, a decline of 20.2% from the May 30th total of 1,790,500 shares. Based on an average daily trading volume, of 528,200 shares, the short-interest ratio is presently 2.7 days. Approximately 2.8% of the company’s stock are short sold.

In related news, EVP Michelle L. Basil sold 7,187 shares of the business’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $103.49, for a total transaction of $743,782.63. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Christopher Simon sold 57,587 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $94.51, for a total value of $5,442,547.37. The disclosure for this sale can be found here. Insiders sold 105,754 shares of company stock valued at $10,455,709 in the last ninety days. Insiders own 1.32% of the company’s stock.

Several hedge funds have recently bought and sold shares of HAE. Welch & Forbes LLC bought a new position in shares of Haemonetics in the 2nd quarter valued at about $241,000. Sheets Smith Wealth Management bought a new position in shares of Haemonetics in the 2nd quarter valued at about $598,000. Retirement Systems of Alabama grew its holdings in shares of Haemonetics by 0.3% in the 2nd quarter. Retirement Systems of Alabama now owns 66,603 shares of the medical instruments supplier’s stock valued at $8,015,000 after acquiring an additional 205 shares in the last quarter. WINTON GROUP Ltd bought a new position in shares of Haemonetics in the 2nd quarter valued at about $3,673,000. Finally, Marshall Wace North America L.P. grew its holdings in shares of Haemonetics by 181.1% in the 1st quarter. Marshall Wace North America L.P. now owns 6,859 shares of the medical instruments supplier’s stock valued at $600,000 after acquiring an additional 4,419 shares in the last quarter. 98.74% of the stock is currently owned by institutional investors.

Shares of HAE traded up $0.99 on Friday, hitting $122.50. The company’s stock had a trading volume of 312,000 shares, compared to its average volume of 485,544. The firm has a market capitalization of $6.21 billion, a P/E ratio of 51.26, a PEG ratio of 3.06 and a beta of 0.82. The company has a quick ratio of 1.62, a current ratio of 2.44 and a debt-to-equity ratio of 0.48. Haemonetics has a fifty-two week low of $80.24 and a fifty-two week high of $123.00. The business has a 50 day moving average price of $111.36.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.06. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The firm had revenue of $249.30 million for the quarter, compared to the consensus estimate of $250.62 million. During the same quarter in the prior year, the business earned $0.43 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, research analysts predict that Haemonetics will post 2.93 earnings per share for the current fiscal year.

Several brokerages recently issued reports on HAE. TheStreet upgraded Rent-A-Center from a “c” rating to a “b-” rating in a research note on Tuesday, May 7th. Raymond James restated a “sell” rating on shares of Inter Pipeline in a research note on Tuesday, May 14th. Zacks Investment Research lowered Glu Mobile from a “buy” rating to a “hold” rating in a research note on Tuesday, April 9th. Finally, Barrington Research set a $22.00 price objective on The Hackett Group and gave the company a “buy” rating in a research note on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Haemonetics has a consensus rating of “Buy” and an average price target of $118.60.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: What moving averages are used to define a golden cross?

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit